ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.540
+0.050 (2.01%)
May 2, 2025, 4:00 PM EDT - Market closed
ImmunityBio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ImmunityBio stock have an average target of 11.35, with a low estimate of 4.75 and a high estimate of 30. The average target predicts an increase of 346.85% from the current stock price of 2.54.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +214.96% | Apr 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,081.10% | Apr 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,081.10% | Apr 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +214.96% | Apr 16, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,081.10% | Apr 15, 2025 |
Financial Forecast
Revenue This Year
100.16M
from 14.75M
Increased by 579.28%
Revenue Next Year
280.41M
from 100.16M
Increased by 179.96%
EPS This Year
-0.52
from -0.62
EPS Next Year
-0.34
from -0.52
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 130.2M | 353.1M | 1.3B | ||
| Avg | 100.2M | 280.4M | 720.5M | ||
| Low | 83.7M | 181.7M | 353.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 783.0% | 252.5% | 349.0% | ||
| Avg | 579.3% | 180.0% | 157.0% | ||
| Low | 467.5% | 81.4% | 25.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.44 | -0.33 | 0.54 | ||
| Avg | -0.52 | -0.34 | 0.08 | ||
| Low | -0.57 | -0.35 | -0.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.